arrow
J

Jean-Yves Blay

lyon 1 universite
H指数:158
被引数:9.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Activity of Low Dose Nivolumab in Patients With Advanced Squamous Cell Carcinomas and Other Cancers

低剂量纳武利尤单抗在晚期鳞状细胞癌及其他癌症患者中的活性

2026-10-200
PRE
Insights into rhabdomyosarcoma in the adolescent and young adult population: a comprehensive clinical study from the French Society of Pediatric Oncology (SFCE) Malignant Mesenchymal Tumor (MMT) Committee and the French Sarcoma Group (GSF-GETO)

青少年和年轻成人横纹肌肉瘤的见解:法国儿科肿瘤学会(SFCE)恶性间质瘤(MMT)委员会和法国肉瘤组(GSF-GETO)的综合性临床研究

2026-09-010
OAAI
Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial

维米塞替尼治疗腱鞘巨细胞瘤患者的多中心、开放标签、II期临床试验

Cancer
IF5.1
2026-08-300
OAAI
Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.

采用C5R方案治疗的原发性中枢神经系统淋巴瘤25年生存情况。

2026-08-300
PRE
Retrospective development and external validation of machine learning models for COVID-19 severity prediction in lung and hematological malignancies: evidence of subtype-specific feature selection bias in joint training

回顾性开发和外部验证用于COVID-19严重程度预测的机器学习模型在肺部和血液恶性肿瘤中的应用:联合训练中存在亚型特异性特征选择偏倚的证据

2026-08-270
OAAI
Myxoid neoplasms with MAP3K kinase fusion: a study of 39 cases

黏液样肿瘤伴MAP3K激酶融合:39例研究

2026-08-190
PRE
Crisis readiness for rare disease populations: learnings and recommendations by the European Reference Networks

罕见病人群的危机准备:欧洲参考网络的经验与建议

2026-08-080
OA
Molecular profiling and access to treatment for rare cancers in Europe

欧洲罕见癌症的分子分型与治疗可及性

2026-07-230
OA
MiT fusions, TSC1–TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa

MiT融合、TSC1–TSC2分化以及干细胞样程序揭示PEComa的不同起源和脆弱性

2026-06-230
OAAI
Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France

局部软组织肉瘤患者接受或不接受辅助化疗的总生存率(DEEPSARC):一项在法国开展的全国性真实世界回顾性队列研究

2026-06-080
OAAI
Characteristics and outcome of intra-abdominal desmoid-type fibromatosis

腹内型硬纤维瘤的特征和预后

2026-05-190
PRE
Molecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomas

EURACAN框架下SPECTA Arcagen研究中的分子谱分析与个性化医学,与法国基因组医学2025计划中AURAGEN平台在腹膜间皮瘤中的比较

2026-05-180
OAAI